Intravenous Iron Isomaltoside 1000 (Monofer®) Compared With Oral Iron in the Treatment of Postgastrectomy Anemia: An Open-label Randomized Controlled Trial
试验速览
- 阶段
- 4 期
- 入组人数
- 358
- 试验地点
- 1
- 主要终点
- Change from Baseline Hemoglobin at 2,4,8 and 12 weeks
研究概览
简要总结
Iron deficiency anemia is a common complication in patients who underwent gastrectomy and leads to a deterioration in patient's quality of life. Therefore iron supplementation is one of the important treatments in postgastrectomy patients.
Taking an oral iron is an option for iron supplementation, but the postgastrectomy patients has poor absorption of iron due to their anatomic change. Accordingly, intravenous iron supplementation has been emerged as another treatment option, but there are only a few studies to evaluate the efficacy of intravenous iron supplementation compared with oral iron in patients underwent gastrectomy.
Therefore, this study aims to evaluate the iron supplementation method as intravenous injection of iron isomaltoside compared with oral iron in the treatment of postgastrectomy anemia.
Gastric cancer patients who underwent curative gastrectomy more than 1 year ago and hemoglobin level lower than 11 g/dL will be included in this trial. After the registration, the patients will be randomly assigned to intravenous iron (n = 179) or oral iron groups (n = 179).
Calculated dose of iron isomaltoside using Ganzoni formula will be injected intravenously in intravenous iron group and 160 mg/day of ferrous sulfate for 12 weeks will be taken in oral iron group. Hemoglobin and iron profiles at baseline and weeks 2, 4, 8, and 12 and quality of life score at baseline and weeks 12 period will be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients ≥20 years of age
- •Underwent gastrectomy for stage I or II of primary gastric adenocarcinoma
- •Hb ≤11.0 g/dL at least one year after surgery
- •Willingness to participate after signing informed consent
排除标准
- •Calculated dosage using the Ganzoni formula >1,500 mg
- •Any medical condition may have caused the patient to be unsuitable for the completion of the study or placed the patient at potential risk from being in the study
- •Underwent chemotherapy or on chemotherapy
- •Drug hypersensitivity to iron isomaltoside
- •Active acute or chronic infections
- •Known intolerance to oral iron treatment
- •History of anemia due to extensive bleeding or causes other than iron deficiency
- •Untreated vitamin B12 or folate deficiency
- •Blood transfusion, Erythropoiesis stimulating agents(ESA), oral iron or intravenous iron treatment within 4 weeks prior to screening
- •History of bone marrow suppression treatment, active Hepatitis B or C, HIV or hematologic disorder other than iron deficiency
- •Iron overload, hematochromatosis or hemosiderosis
- •Pregnancy or nursing
- •Creatinine clearance rate using Cockcroft-Gault formula <30 mL/min
- •Participation in any other clinical study within one month prior to screening
研究组 & 干预措施
IV iron (Monofer) group
Iron isomaltoside(Monofer) will be injected intravenously and injection dose will be calculated using Ganzoni formula.
干预措施: iron isomaltoside (Monofer) intravenous infusion (Drug)
Oral iron group
Ferrous sulfate(Feroba-YOU) 160mg/day for 12 weeks will be taken per oral.
干预措施: Ferrous sulfate(Feroba-YOU) per oral (Drug)
结局指标
主要结局
Change from Baseline Hemoglobin at 2,4,8 and 12 weeks
时间窗: at Baseline and weeks 2, 4, 8, and 12
次要结局
- QOL (quality of life) of the patients(at Baseline and weeks 2, 4, 8, and 12)
- transferrin saturation(at Baseline and weeks 2, 4, 8, and 12)
- serum ferritin(at Baseline and weeks 2, 4, 8, and 12)
- serum iron(at Baseline and weeks 2, 4, 8, and 12)
- serum transferrin(at Baseline and weeks 2, 4, 8, and 12)